$OPGN News

Last published 2y ago

2y agoOPGNOpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QGlobeNewswireROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company
2y agoOPGNOpGen Announced 1-for-10 Reverse Stock SplitGlobeNewswireROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of
2y agoOPGNOpGen Provides Update on Business Operations and Strategic OpportunitiesGlobeNewswireROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of
2y agoOPGNOpGen Receives Nasdaq Notice Regarding Delayed Form 10-KGlobeNewswireROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company
2y agoOPGNOpGen Announces Acquisition of Preferred Stock by David LazarGlobeNewswireDavid Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE
2y agoOPGNOpGen Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireTotal revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including
3y agoOPGNOpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross ProceedsGlobeNewswireROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company"), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat
3y agoOPGNOpGen, Inc. (OPGN) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoOPGNOpGen Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireTotal revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract
3y agoOPGNOpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud OfferingGlobeNewswireSingle nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists Signed first large commercial contract with U.S.
3y agoOPGNOpGen's Subsidiary Curetis and FIND Extend R&D Collaboration AgreementGlobeNewswireSigned contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICsNext phase to cover full AMR assay and cartridge development, analytical
3y agoOPGNOpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern TimeGlobeNewswireROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial
3y agoOPGNOpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FINDGlobeNewswireAll milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone payment of
3y agoOPGNOpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in EuropeGlobeNewswirePatent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of European Patent Office
3y agoOPGNOpGen's Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 InstrumentsGlobeNewswireFollowing final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been receivedLatest C-Series Unyvero A30 instruments optimized for series production and clinical trials ROCKVILLE, Md.,
3y agoOPGNOpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 ConferenceGlobeNewswire‘Multi-Center Clinical Trial Using a Novel Semi-Quantitative Multiplex-PCR Based Diagnostic Panel for Urinary Tract Specimens' presented on June 17th, 2023Presentation focused on primary study endpoint and
3y agoOPGNOpGen Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireTotal revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA
3y agoOPGNOpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern TimeGlobeNewswireROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its first quarter 2023 financial results
3y agoOPGNOpGen Announces Closing of $3.5 Million Public OfferingGlobeNewswireROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
3y agoOPGNOpGen Announces Pricing of $3.5 Million Public OfferingGlobeNewswireROCKVILLE, Md., May 01, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
3y agoOPGNOpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher HealthcareGlobeNewswireFisher Healthcare, a part of Thermo Fisher Scientific, will become the non-exclusive national laboratory distribution partner alongside OpGen, Inc.'s direct sales in the U.S. for the Unyvero A50 platformInitial focus on
3y agoOPGNOpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection PanelGlobeNewswireBased on large multi-center study with over 1,800 patient samplesPrimary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of 96.8% and overall
3y agoOPGNOpGen's Subsidiary Curetis Signs Expansion of R&D Collaboration with FINDGlobeNewswireParties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN,
3y agoOPGNOpGen's Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnosticsGlobeNewswirePREPLEX project is part of broader InfectoGnostics Research Campus in Jena, GermanyTotal project volume of PREPLEX collaborative research is approximately $ 0.9 Mio ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) --
3y agoOPGNOpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswireTotal revenue for 2022 was approximately $2.6 millionBalance sheet strengthened by recently closed public offering with gross proceeds of $7.5 millionConference call to be held March 29, 2023 at 4:30 p.m. ET ROCKVILLE,
3y agoOPGNOpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern TimeGlobeNewswireROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its fourth quarter and full year 2022
3y agoOPGNOpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business GrowthGlobeNewswireApproximately 5,000 sq. ft. facility houses laboratory and administrative operations under one location for future growth of businessARESdb, the company's AMR knowledge database, has grown by 28% in Q1-2023 with now over
3y agoOPGNOpGen Announces Exercise of All Prefunded WarrantsGlobeNewswireROCKVILLE, Md., Feb. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
3y agoOPGNOpGen subsidiary Ares Genetics announces granting of key patent in ChinaGlobeNewswirePatent covers the identification and diagnostic use of genomic variants for the diagnosis of antibiotic resistant bacteriaThe China National Intellectual Property Administration (CNIPA) has granted patent ZL
3y agoOPGNOpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business UpdateGlobeNewswirePreliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of December 31, 2022 was approximately $7.4 millionBalance sheet strengthened by recently closed
3y agoOPGNOpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration ProjectGlobeNewswireROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
3y agoOPGNOpGen Announces Closing of $7.5 Million Public OfferingGlobeNewswireROCKVILLE, Md., Jan. 11, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
3y agoOPGNOpGen Announces Pricing of $7.5 Million Public OfferingGlobeNewswireROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
3y agoOPGNOpGen Announced 1-for-20 Reverse Stock SplitGlobeNewswireROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
3y agoOPGNOpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection PanelGlobeNewswireStudy has enrolled over 1,800 patient samples at 4 U.S. clinical trial sitesPrimary endpoint for Unyvero UTI for urinary tract infection shows overall weighted average sensitivity of 96.4% and overall weighted average
4y agoOPGNOpGen Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireCompletes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero
4y agoOPGNOpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business UpdateGlobeNewswirePreliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and as of October 3, 2022 was approximately $13.3 millionAdditional customer contract for
4y agoOPGNOpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard TimeGlobeNewswireROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its third quarter 2022 financial results
4y agoOPGNOpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial SupportGlobeNewswireUnyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100Focus on the detection of pneumonia patients infected with Acinetobacter baumannii ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25,
4y agoOPGNOpGen Announces Closing of $3.38 Million Registered Direct OfferingGlobeNewswireROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or the "Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced th
4y agoOPGNOpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection PanelGlobeNewswireProspective multicenter trial for the Unyvero UTI Panel has successfully completed enrollment of patient samples Urine samples have been collected from over 1,800 patients at 4 U.S. clinical trial sites Clinical performance evaluation aims at a subseq
4y agoOPGNOpGen Announces $3.38 Million Registered Direct OfferingGlobeNewswireROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or the "Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced t
4y agoOPGNOpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ PlatformGlobeNewswireFIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs) Initial project focuses on feasibility study for the rapid detection of antimicrobial r
4y agoOPGNOpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen"))), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held as a hyb
4y agoOPGNNasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price RequirementGlobeNewswireROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen"))), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has received w
4y agoOPGNOpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland LaboratoryGlobeNewswireExpanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth opportunity Services at launch include rapid turnaround sequencing of clinical isolates, unique and differentiated interpretative services
4y agoOPGNOpGen Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireTotal Q2 2022 revenues of $1.0 million with product sales a key growth driver First two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022 Requested additional 180-day period to regain compliance with Nasdaq minimum
4y agoOPGNOpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern TimeGlobeNewswireROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2022 financial results after the close of the U.S. fina
4y agoOPGNOpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ LeuvenGlobeNewswireCollaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST) Ares plans to strategically expand its proprietary AMR knowledgebase ARESdb with data
4y agoOPGNOpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business UpdateGlobeNewswirePreliminary Total Revenue for Q2 2022 was approximately $1.0 million Cash as of June 30, 2022 was approximately $16.6 million First commercial customer contract for Acuitas AMR Gene Panel signed in June 2022 ROCKVILLE, Md., July 08, 2022 (GLOB